hackint0sh/New-Dataset huggingface dataset:
The monitoring of dnDSA after KT and an indication graft biopsy in case of appearance, even in the absence of graft dysfunction, is not part of a routine clinical practice in all KT centers. This strategy could be a valuable option, in order to begin treatment of ABMR before graft dysfunction occurs, and therefore to improve prognosis associated with phenotype 2 ABMR. Parajuli et al.4 suggested that early diagnosis and treatment of sABMR with SOC, using DSA monitoring may improve outcomes after KT, but this is a retrospective and no-randomized study. This study will be the first prospective randomized study in the context of de novo DSA. We will evaluate a new combination of treatment for ABMR in the context of dnDSA with subclinical lesions and in the same time may help to determine the real incidence of sABMR in KT recipients with subclinical dnDSA. The use of belatacept in the context of sABMR to improve the non-adherence and to decrease the endothelial toxicity had never been evaluated in a prospective way. conditions: Kidney Transplant Rejection studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 290 type: ESTIMATED name: Conversion to Belatacep name: Standard of care treatment (SOC regimen) with Tacrolimus measure: The efficacy of belatacept combined with standard of care, compared to calcineurin inhibitors (CNI) combined with standard of care, among kidney transplant recipients with sABMR sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06291090 id: 22-0789 id: K08DA049905 type: NIH link: https://reporter.nih.gov/quickSearch/K08DA049905 briefTitle: A Multi-site Intervention to Expand Hospital Based OUD Treatment Provision overallStatus: RECRUITING date: 2023-01-18 date: 2024-04-30 date: 2025-05-01 date: 2024-03-04 date: 2024-03-29 name: University of Colorado, Denver class: OTHER name: National Institute on Drug Abuse (NIDA) briefSummary: The investigators implemented a multi-site hospital-based opioid use disorder (OUD) treatment intervention across 12 hospitals in Colorado to address an OUD treatment gap among hospitalized adults with OUD. conditions: Opioid Use Disorder studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This intervention will be implemented across 12 hospitals primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 400 type: ESTIMATED name: OUD treatment intervention measure: Change in buprenorphine prescribing at hospital discharge measure: Change in rates of methadone prescribing during hospitalization measure: Change in average (mean) COWS score over time measure: Change in naloxone prescribing at hospital discharge sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Colorado Anschutz Medicl Campus status: RECRUITING city: Aurora state: Colorado zip: 80045 country: United States name: Susan L Calcaterra, MD role: CONTACT phone: 248-703-5947 email: susan.calcaterra@cuanschutz.edu lat: 39.72943 lon: -104.83192 hasResults: False
nctId: NCT06291077 id: 2021/0391/HP briefTitle: Comparison of the Effects of Belatacept and Anticalcineurins on Endothelial Function in Renal Transplant Patients - <BELAFENDO> acronym: BELAFENDO overallStatus: NOT_YET_RECRUITING date: 2025-01-01 date: 2028-01-01 date: 2028-01-01 date: 2024-03-04 date: 2024-03-04 name: University Hospital, Rouen class: OTHER briefSummary: Kidney transplantation is the standard treatment for patients with end-stage renal failure.
However, anticalcineurin inhibitors, the most widely used immunosuppressants, are involved in the occurrence of cardiovascular events, a major cause of premature death in these patients. They play an important role in the occurrence of endothelial dysfunction and increased arterial stiffness by decreasing the synthesis of nitric oxide (NO), promoting intrarenal arterial vasoconstriction and stimulating the production of pro-inflammatory cytokines. leading to the development of hypertension and chronic graft dysfunction.
Belatacept, a more recently developed immunosuppressant and co-stimulation signal inhibitor, has shown an anti-rejection effect similar to cyclosporine with a better cardiovascular tolerance profile. Preliminary studies are contradictory on the influence of Belatacept on arterial stiffness. Furthermore, to date, no study has evaluated the impact of Belatacept on vasomotor endothelial function in humans, an indicator of NO bioavailability. The interest of this study is to demonstrate that patients taking Belatacept have an improvement in vascular function compared to patients taking anticalcineurins in order to consider an earlier change in immunosuppressive strategy in the event of vascular damage. conditions: Kidney Diseases studyType: INTERVENTIONAL phases: PHASE4 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 44 type: ESTIMATED name: Belatacept name: anticalcineurins measure: Replacement of anticalcineurins with Belatacept in kidney transplant patients allows an improvement in the endothelium-dependent dilation of peripheral conductance arteries sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06291064 id: IRB23-0678 briefTitle: Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer acronym: TARMAC overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2029-06 date: 2032-06 date: 2024-03-04 date: 2024-03-04 name: University of Chicago class: OTHER briefSummary: The primary purpose of this study is to determine what proportion of participants will achieve complete pathological response with epirubicin+ cyclophosphamide followed by docetaxel +carboplatin. This will also examine the potential of using signals in the blood (biomarkers) to identify resistance to chemotherapy in Nigerian women with triple negative breast cancer (TNBC).
All enrollment to this trial will occur at sites in Nigeria. University of Chicago is serving as coordinating center and will be involved in data analysis. conditions: Triple Negative Breast Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 85 type: ESTIMATED name: Cyclophosphamide name: Epirubicin name: Docetaxel name: Carboplatin name: Breast Surgery name: Capecitabine measure: Percentage of Participants that Achieve Pathologic Complete Response (pCR) Rate (Breast) measure: Percentage of Participants that Achieve Pathologic Complete Response (pCR) Rate (Lymph Nodes) measure: Percentage of Participants that Achieve Pathologic Complete Response (pCR) Rate (By Stage) measure: Side Effects of the Study Pre-surgery Chemotherapy Regimen measure: Clinical Response measure: Progressive Disease measure: Invasive Disease Free Survival (iDFS) measure: Duration of Response measure: Heart Related Side Effects of the Pre-Surgery Chemotherapy Regimen sex: FEMALE minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06291051 id: 2021/0382/HP briefTitle: Evaluation of the Safety of Electrical Spinal Cord Stimulation in Parkinson's Patients Presenting With Painful Camptocormia acronym: CAMPTOSTIM overallStatus: NOT_YET_RECRUITING date: 2024-10-01 date: 2028-01-01 date: 2028-01-01 date: 2024-03-04 date: 2024-03-04 name: University Hospital, Rouen class: OTHER briefSummary: Camptocormia is defined by abnormal flexion of the trunk, not fixed, present when standing and walking, resolves when lying down and often complicated by lower back pain. It can be observed in numerous neurological pathologies with a prevalence ranging between 5 and 19% in Parkinson's disease. The physiopathology of camptocormia associated with PD is not completely elucidated, however several mechanisms are discussed, including muscular hypertonia, abdominal muscle dystonia, proprioceptive deficit, iatrogenics linked to dopamine agonists, and focal myopathy. Although its impact is major and greater than the main symptoms of the disease, no specific treatment has been the subject of a marketing authorization request in this indication. Its management remains difficult and usually consists of: adjusting the antiparkinsonian treatment, reducing or even eliminating dopamine agonists, resorting to botulinum toxin injections and rehabilitation, sometimes with the use of a corset. However, the results observed are most often disappointing. The benefit of more invasive techniques, such as deep brain stimulation, classically proposed in advanced forms at the stage of motor complications of PD, is discussed by certain authors. Numerous studies thus suggest that bilateral stimulation of the NST could have a significant but moderate beneficial effect on postural disorders associated with PD, in particular on camptocormia. Likewise, the results of a retrospective study recently conducted in 36 Parkinson's patients discuss the effectiveness of bi-pallidal stimulation. Furthermore, surgical interventions by arthrodesis remain invasive and cause more frequent complications in Parkinson's patients with camptocormia compared to patients with isolated degenerative spinal pathology.
Electrical spinal cord stimulation (ESS) is a validated technique in the management of chronic neuropathic pain. Several publications suggest that it could be effective on postural disorders in PD. Thus, authors report the case of a Parkinson's patient afflicted with painful camptocormia refractory to drug treatments and deep brain stimulation who benefited from EMS with a remarkable effect on pain, walking and posture. This observation is corroborated by data collected in 3 Parkinson's patients with camptocormia subjected to EMS with a beneficial effect on painful and motor symptoms. The mechanism of action could be linked to the correction of the proprioceptive deficit via ascending stimulation of the basal ganglia. On the other hand, the effectiveness of repetitive spinal cord magnetic stimulation was evaluated in a study carried out in 37 patients with camptocormia associated with PD. conditions: Parkinson Disease studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 6 type: ESTIMATED name: Electrical spinal cord stimulation measure: Evaluation of the safety of electrical spinal cord stimulation in Parkinson's patients with painful camptocormia sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06291038 id: 2021/0381/HP briefTitle: Efficacy of Glutamine Supplementation in Patients Suffering From Irritable Bowel Syndrome With Impaired Intestinal Permeability acronym: MISSISIIPI overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2029-03-01 date: 2029-03-01 date: 2024-03-04 date: 2024-03-04 name: University Hospital, Rouen class: OTHER briefSummary: Irritable bowel syndrome (IBS) affects approximately 5% of the general population and remains a daily problem in the practice of clinicians with inconsistent effectiveness of treatments while patients' expectations are high.
Glutamine is a non-essential amino acid which regulates numerous metabolic pathways, and which plays a key role in the intestine because it is the preferential substrate of enterocytes and immune cells. Ex vivo, glutamine is able to restore the expression of tight junction proteins in patients suffering from IBS-D. On the other hand, glutamine supplementation is capable of reducing abdominal pain and restoring intestinal permeability disorders in a subgroup of patients with intestinal permeability disorder (post-infectious IBS-D).
Our working hypothesis would be that all patients suffering from IBS with permeability disorder, measured by the lactulose/mannitol test, could benefit from oral glutamine supplementation. conditions: Irritable Bowel Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Multicentric; prospective; randomized; double blind; interregional primaryPurpose: TREATMENT masking: SINGLE maskingDescription: double blind whoMasked: PARTICIPANT count: 60 type: ESTIMATED name: • Experimental group: treatment with glutamine at a dose of 5g 3 times a day for 8 weeks name: • Control group: treatment with a protein powder (Protifar) (Placébo) 5g 3 times a day for 8 weeks. measure: Evaluate the symptomatic effectiveness of glutamine supplementation in patients suffering from IBS-D with increased intestinal permeability sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06291012 id: RECHMPL22_0399 id: 2024-512236-30-00 type: REGISTRY domain: EUCT Number briefTitle: Stopping Pneumonia Antibiotherapy Regimen Early acronym: SPARE overallStatus: NOT_YET_RECRUITING date: 2024-09-01 date: 2027-05-01 date: 2027-09-01 date: 2024-03-04 date: 2024-03-04 name: University Hospital, Montpellier class: OTHER name: Direction Générale de l'Offre de Soins briefSummary: The hypothesis for this trial is that an antibiotic strategy for the management of non-severe community-acquired alveolar pneumonia in children aged 3 to 59 months, including amoxicillin 80-100 mg/kg/day for at least 3 days in case of rapid response and 5 days in case of delayed response, would not be inferior to current French recommendations (antibiotic therapy for 5 days in case of rapid response and 7 days in case of delayed response) in terms of treatment of failure rate at 7 days. conditions: Community-acquired Pneumonia conditions: Child, Only studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The randomization will be carried out by minimization with stratification on the investigating center and age (\< 1 year and ≥ 1 year) primaryPurpose: TREATMENT masking: SINGLE whoMasked: CARE_PROVIDER count: 1100 type: ESTIMATED name: Quick response: Amoxicillin for 3 days name: Delayed response: Amoxicillin for 5 days name: Quick response: Amoxicillin for 5 days name: Delayed response: Amoxicillin for 7 days measure: Therapeutic failure rate D7 measure: Therapeutic failure rate on D30 measure: Adverse effects measure: Compliance measure: Duration of antibiotic therapy sex: ALL minimumAge: 3 Months maximumAge: 59 Months stdAges: CHILD facility: CHU de Montpellier city: Montpellier zip: 34295 country: France name: Sarah DUTRON, MD role: CONTACT name: Sarah DUTRON, MD role: PRINCIPAL_INVESTIGATOR name: Eric JEZIORSKI, MD PhD role: SUB_INVESTIGATOR lat: 43.61092 lon: 3.87723 hasResults: False
nctId: NCT06290999 id: CHUBX 2023/80 briefTitle: Study of Multifrequential Impedancemetry in Pulsatile Tinnitus acronym: MADMAN overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2025-09-15 date: 2025-12-15 date: 2024-03-04 date: 2024-03-04 name: University Hospital, Bordeaux class: OTHER briefSummary: This study intended to search for a relationship between the multifrequential admittancemetry and the pulsatile tinnitus. conditions: Pulsatile Tinnitus studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: multifrequential admittancemetry measure: Multifrequency admittancemetry measure: compression maneuvers measure: Evaluation of the effect of interventional radiology measure: success of radiointerventional treatment sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Bordeaux University Hospital city: Bordeaux zip: 33000 country: France name: Balthazar CROC role: CONTACT email: balthazar.croc@chu-bordeaux.fr name: Valérie FRANCO-VIDAL, Pr role: CONTACT phone: 0556795609 email: valerie.vidal@chu-bordeaux.fr lat: 44.84044 lon: -0.5805 hasResults: False
nctId: NCT06290986 id: Pyrocardan® RCT briefTitle: Pyrocardan® Implant Arthroplasty or LRTI for Trapeziometacarpal Osteoarthritis overallStatus: RECRUITING date: 2022-09-26 date: 2025-09-30 date: 2025-09-30 date: 2024-03-04 date: 2024-03-04 name: Herlev and Gentofte Hospital class: OTHER briefSummary: This is a randomized controlled trial comparing the Pyrocardan® implant (intervention group) with the standard ligament reconstruction and tendon interposition (LRTI) (control group). All Danish citizens with osteoarthritis of the thumb carpometacarpal joint referred to the orthopedic department at Copenhagen University Hospital in Herlev/Gentofte will be considered for participation in the trial. The following exclude from participation in the study: Below 40 years of age; cognitive or linguistic impairment; osteoarthritis of other carpal bones; previous surgery in the carpometacarpal joint; patients with rheumatoid arthritis. A total of 64 patients will be included. The primary outcome is the patient reported outcomes questionnaire; Quick-DASH. The secondary outcomes are patient-reported outcomes, functional outcomes, radiographic outcomes, readmission, complications, revisions. The patients are examined before surgery and 3, 6, 12 and 24 months after the operation. The patients are also contacted after 5 and 10 years. conditions: CMC-1 Osteoarthritis conditions: Trapeziometacarpal Osteoarthritis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 64 type: ESTIMATED name: Pyrocardan® implant name: Ligament reconstruction and tendon interposition (LRTI) measure: Patient-reported outcome: QuickDASH measure: Patient-reported outcome measure: Strength measurements measure: Radiographs measure: Return to occupation sex: ALL minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Herlev and Gentofte Hospital status: RECRUITING city: Hellerup zip: 2900 country: Denmark name: Jens Jørgsholm, MD role: CONTACT phone: +4551339705 email: Jens.bertel.joergsholm.01@regionh.dk name: Rasmus Wejnold Jørgensen, MD, PhD role: CONTACT phone: +4538673315 email: rasmus.wejnold.joergensen@regionh.dk lat: 55.73204 lon: 12.57093 hasResults: False
nctId: NCT06290973 id: PI-23-3017 briefTitle: Quality of Life and Health Perception After Surgery of Varicose Veins overallStatus: COMPLETED date: 2023-01-02 date: 2023-02-28 date: 2023-11-14 date: 2024-03-04 date: 2024-03-04 name: Hospital Clínico Universitario de Valladolid class: OTHER briefSummary: The aim of this study is to analyze changes in health perception and quality of life in patients after surgery for varicose veins using clinical score VCSS and QoL scores SF12 as general health questionary and Veines QoL/Sym as disease specific questionary. conditions: Quality of Life conditions: Varicose Veins studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 58 type: ACTUAL name: surgery of varicose veins measure: changes in qol questionarie SF-12 after surgery of varicose veins measure: changes in qol questionarie Veines QoL/Sym after surgery of measure: changes in VCSS after surgery of varicose veins sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital CLínico Universitario de Valladolid city: Valladolid country: Spain lat: 41.65518 lon: -4.72372 hasResults: False
nctId: NCT06290947 id: BFR-AE-DT2-2023-01 id: IRB 2022/C/20/N type: OTHER_GRANT domain: AAUP briefTitle: BFR Walking for Insulin and Aerobic Improvement in Type 2 Diabetes acronym: BRAID overallStatus: COMPLETED date: 2022-03-06 date: 2023-12-20 date: 2024-01-08 date: 2024-03-04 date: 2024-03-04 name: Arab American University (Palestine) class: OTHER briefSummary: This clinical trial examines the impact of Blood-Flow Restriction Walk Training (BFRw) on insulin sensitivity and aerobic capacity in individuals with Type 2 Diabetes (T2D).
Hemoglobin A1c (HbA1c) levels and maximal oxygen consumption (VO2 max) are monitored as indicators of insulin sensitivity and aerobic capacity, respectively. conditions: Type 2 Diabetes Mellitus studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This study employs a randomized controlled trial model with a parallel assignment to evaluate the efficacy of Blood-Flow Restriction Walk Training compared to a control condition. Participants are randomly allocated into two groups: one receiving the intervention (BFR walk training) and the other serving as a control (usual walk training). This design allows for the direct comparison of outcomes between the intervention and control groups over the study period. primaryPurpose: SUPPORTIVE_CARE masking: NONE maskingDescription: None (Open Label) count: 60 type: ACTUAL name: BFR Cuffs for Intervention Group name: Standard Walking Training Program measure: Improvement in Insulin Sensitivity measure: Improvement in Aerobic Capacity measure: Change in Body Mass Index (BMI) sex: MALE minimumAge: 40 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Arab American University - Palestine city: Jenin zip: P.O Box 24 country: Palestinian Territory, occupied lat: 32.45943 lon: 35.30086 hasResults: False
nctId: NCT06290934 id: GS-US-409-5704 id: 2023-508304-38 type: OTHER domain: European Medicines Agency briefTitle: Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis acronym: SWIFT overallStatus: RECRUITING date: 2024-03-27 date: 2027-05 date: 2028-03 date: 2024-03-04 date: 2024-04-23 name: Gilead Sciences class: INDUSTRY briefSummary: The goal of this study is to learn if GS-1427 is effective and safe in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with GS-1427 with participants treated with placebo (Part 1), and participants treated with GS-1427 or ustekinumab alone with participants treated with GS-1427 in combination with ustekinumab (Part 2).
nctId: NCT06290921 id: 3472 briefTitle: Ovulation Triggering 2 vs 3 Follicles overallStatus: ACTIVE_NOT_RECRUITING date: 2024-02-22 date: 2024-12-31 date: 2025-02-20 date: 2024-03-04 date: 2024-03-04 name: Clinique Ovo class: INDUSTRY briefSummary: Poor responders in in-vitro fertilization (IVF) cycles represent a major challenge for fertility specialists. Although poor responders tend to have sub-optimal fertility treatment outcomes, many of these patients wish to attempt at least one IVF cycle. Traditionally, IVF cycles producing less than 3 to 4 mature follicles (measuring at least 14 mm) have either been cancelled or converted to intra-uterine insemination (IUI) due to the low pregnancy rates associated with these cycles. The minimal number of follicles required to proceed with egg collection is based on clinical experience, having been determined by weighing the probability of implantation and pregnancy versus the risk of not obtaining quality oocytes or reaching embryo transfer when fewer mature follicles are present. This retrospective quality control study aims to compare pregnancy rates in IVF cycles producing 3 follicles measuring 14 mm and more on trigger day, versus 2 or fewer follicles. conditions: Infertility studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 400 type: ESTIMATED name: Ovulation triggering measure: Clinical Pregnancy Rate sex: FEMALE minimumAge: 18 Years maximumAge: 42 Years stdAges: ADULT facility: Clinique Ovo city: Montréal state: Quebec zip: H4P 2S4 country: Canada lat: 45.50884 lon: -73.58781 hasResults: False